Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
Abstract Background Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin (AVP), which is involved in many pathophysiologic processes in...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-020-1710-6 |
id |
doaj-983b6db0075d442eb7875c35dfc7d564 |
---|---|
record_format |
Article |
spelling |
doaj-983b6db0075d442eb7875c35dfc7d5642021-02-07T12:49:05ZengBMCBMC Nephrology1471-23692020-02-012111810.1186/s12882-020-1710-6Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5Edyta Golembiewska0Abdul Rashid Qureshi1Lu Dai2Bengt Lindholm3Olof Heimbürger4Magnus Söderberg5Torkel B. Brismar6Jonaz Ripsweden7Peter Barany8Richard J. Johnson9Peter Stenvinkel10Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergCardiovascular, Renal and Metabolism Safety, Clinical Pharmacology & Safety Sciences R&D, AstraZenecaDivision of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Diseases and Hypertension, School of Medicine, University of ColoradoDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergAbstract Background Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin (AVP), which is involved in many pathophysiologic processes in CKD. The aim of the present study was to explore the association of copeptin with VC in CKD stage 5. Methods Copeptin was investigated in conjunction with living donor kidney transplantation in 149 clinically stable CKD stage 5 patients (CKD5), including 53 non-dialyzed (CKD5-ND) and 96 dialysis patients treated by peritoneal dialysis (PD) (n = 43) or hemodialysis (HD) (n = 53). We analyzed the association of copeptin with presence and extent of VC ascertained both histologically in biopsies from the inferior epigastric artery (n = 137) and by coronary artery calcification (CAC) score measured by computed tomography. Results Patients with higher copeptin were older, had higher systolic blood pressure, higher prevalence of CVD and their preceding time on chronic dialysis was longer. In Spearman’s rank correlations (Rho), copeptin concentrations were significantly associated with CAC score (Rho = 0.27; p = 0.003) and presence of medial VC (Rho = 0.21; p = 0.016). Multivariate logistic regression analysis showed that 1-SD higher age, male gender, diabetes and 1-SD higher copeptin were significantly associated with the presence of moderate-extensive VC. Conclusions High circulating levels of copeptin in CKD5 patients are independently associated with the degree of medial calcification ascertained by histology of arterial biopsies. Thus, plasma copeptin may serve as a marker of the uremic calcification process.https://doi.org/10.1186/s12882-020-1710-6CopeptinChronic kidney diseaseEnd-stage renal diseaseVascular calcification |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Edyta Golembiewska Abdul Rashid Qureshi Lu Dai Bengt Lindholm Olof Heimbürger Magnus Söderberg Torkel B. Brismar Jonaz Ripsweden Peter Barany Richard J. Johnson Peter Stenvinkel |
spellingShingle |
Edyta Golembiewska Abdul Rashid Qureshi Lu Dai Bengt Lindholm Olof Heimbürger Magnus Söderberg Torkel B. Brismar Jonaz Ripsweden Peter Barany Richard J. Johnson Peter Stenvinkel Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 BMC Nephrology Copeptin Chronic kidney disease End-stage renal disease Vascular calcification |
author_facet |
Edyta Golembiewska Abdul Rashid Qureshi Lu Dai Bengt Lindholm Olof Heimbürger Magnus Söderberg Torkel B. Brismar Jonaz Ripsweden Peter Barany Richard J. Johnson Peter Stenvinkel |
author_sort |
Edyta Golembiewska |
title |
Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 |
title_short |
Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 |
title_full |
Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 |
title_fullStr |
Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 |
title_full_unstemmed |
Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 |
title_sort |
copeptin is independently associated with vascular calcification in chronic kidney disease stage 5 |
publisher |
BMC |
series |
BMC Nephrology |
issn |
1471-2369 |
publishDate |
2020-02-01 |
description |
Abstract Background Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin (AVP), which is involved in many pathophysiologic processes in CKD. The aim of the present study was to explore the association of copeptin with VC in CKD stage 5. Methods Copeptin was investigated in conjunction with living donor kidney transplantation in 149 clinically stable CKD stage 5 patients (CKD5), including 53 non-dialyzed (CKD5-ND) and 96 dialysis patients treated by peritoneal dialysis (PD) (n = 43) or hemodialysis (HD) (n = 53). We analyzed the association of copeptin with presence and extent of VC ascertained both histologically in biopsies from the inferior epigastric artery (n = 137) and by coronary artery calcification (CAC) score measured by computed tomography. Results Patients with higher copeptin were older, had higher systolic blood pressure, higher prevalence of CVD and their preceding time on chronic dialysis was longer. In Spearman’s rank correlations (Rho), copeptin concentrations were significantly associated with CAC score (Rho = 0.27; p = 0.003) and presence of medial VC (Rho = 0.21; p = 0.016). Multivariate logistic regression analysis showed that 1-SD higher age, male gender, diabetes and 1-SD higher copeptin were significantly associated with the presence of moderate-extensive VC. Conclusions High circulating levels of copeptin in CKD5 patients are independently associated with the degree of medial calcification ascertained by histology of arterial biopsies. Thus, plasma copeptin may serve as a marker of the uremic calcification process. |
topic |
Copeptin Chronic kidney disease End-stage renal disease Vascular calcification |
url |
https://doi.org/10.1186/s12882-020-1710-6 |
work_keys_str_mv |
AT edytagolembiewska copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT abdulrashidqureshi copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT ludai copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT bengtlindholm copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT olofheimburger copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT magnussoderberg copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT torkelbbrismar copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT jonazripsweden copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT peterbarany copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT richardjjohnson copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 AT peterstenvinkel copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5 |
_version_ |
1724280655833989120 |